Ainos, Inc.
AIMDW
NASDAQ Global Market0.13
USD
-0.01
- -
CIK
0001014763
ISIN
US00902F1131
CUSIP
00902F113
Return %
Stock
S&P500
1Y
-0.31
26.53
3Y
-38.93
76.60
5Y
-82.72
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Chun-Hsien Tsai
- Full Time Employees
- 44
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8880 Rio San Diego Drive San Diego TX United States of America 92108
- IPO Date
- Jan 8, 2021
- CIK
- 0001014763
- Website
- ainos.com
- Similar Companies
- Business
- Ainos, Inc. (NASDAQ: AIMD; AIMDW) is a dual-platform AI and biotech company that develops and commercializes SmellTech solutions, AI-powered diagnostics, and low-dose interferon-alpha therapeutics. The company offers its proprietary AI Nose platform, which employs a smell language model to digitize scents into machine-readable Smell IDs for applications in volatile organic compound detection, point-of-care testing, semiconductor fabrication, smart factories, robotics, senior care, women's health, hospital infection management, and environmental monitoring; VELDONA, a clinical-stage low-dose oral interferon-alpha targeting rare diseases such as HIV-related oral warts and primary Sjögren’s syndrome, infectious conditions including common cold and influenza, autoimmune disorders, and animal health issues like feline chronic gingivostomatitis, allergies, skin and gum problems, and weight-related discomfort in pets and humans; VOC-based point-of-care tests including Ainos Flora for female vaginal health and sexually transmitted infections, Ainos Pen, and CHS430; and legacy products such as COVID-19 antigen rapid test kits. Headquartered in San Diego, California, and founded in 1984 as Amarillo Biosciences, Inc., which changed its name to Ainos, Inc. in May 2021, the company operates primarily in the United States with global partnerships focused on Asia; it functions as a subsidiary of Taiwan Carbon Nano Technology Corporation and maintains research and development collaborations across healthcare, industrial sensing, and medtech sectors targeting enterprise clients, healthcare providers, and veterinary markets. Recent developments include a $2.1 million three-year subscription-based AI Nose order from ASE Technology Holding Co., Ltd. in 2025; strategic alliances with Topco for global distribution, Kenmec Mechanical Engineering for industrial automation showcased at Automation Taipei and SEMICON Taiwan 2025, ugo for service robots with olfactory capabilities, Solomon Technology Corporation, and Nisshinbo Micro Devices for VOC platform co-development; the debut of the world's first patented portable, cloud-connected AI Nose device with SmellTech-as-a-Service subscriptions; a 1-for-5 reverse stock split effective June 30, 2025; and $1.75 million follow-on funding in early 2024 to support VELDONA investigational new drug preparations and AI Nose advancements.
Ainos, Inc. (NASDAQ:AIMDW) Sees Significant Decrease in Short Interest